<DOC>
	<DOCNO>NCT02588001</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety enzalutamide patient non-metastatic castration resistant prostate cancer . The total duration study 5 year . All patient receive enzalutamide 160 mg ( four 40 mg capsule ) orally daily . The treatment start Visit 0 within one week enrollment . Visit 1 2 week treatment start ; clinical assessment conduct adverse event Japanese version Functional Assessment Cancer Therapy-Prostate ( FACT-P ) scale . Patients consider adequate investigator continue treatment 12-week cycle visit ( counted initial dose ) patient meet withdrawal criterion . Patients follow 2 3 year enrollment 3 year last participant enrollment . The end study define follow-up assessment date 3 year last participant enrollment . Patients primarily assess prostate-specific antigen ( PSA ) progression-free survival ( PFS ) .</brief_summary>
	<brief_title>Japanese Research Patients With Non-metastatic Castration Resistant Prostate Cancer - Enzalutamide</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm prostate cancer 2 . Patients history radical prostatectomy radiation therapy radical treatment 3 . Patients receive continuous androgen deprivation therapy use gonadotropinreleasing hormone ( GnRH ) agonist antagonist , use surgical castration 4 . Patients serum testosterone 1.73 nmol/L ( 0.50 ng/dL ) less 5 . Patients history bicalutamide flutamide time first recurrence confirm since radical treatment complete 6 . Patients 3 increase PSA test result measure consecutively least one week apart androgen deprivation therapy 7 . Patients serum PSA 2 micrograms/L ( 2 ng/mL ) 8 . Patients confirm remote metastasis diagnosis prostate cancer ( exclude lymph node metastasis minor axis le 15 mm consider nonmeasurable Response Evaluation Criteria In Solid Tumors ( RECIST ) version 1.1 ) 9 . Patients asymptomatic prostate cancer 10 . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status 01 11 . Patients life expectancy least 12 month 12 . Patients sign write informed consent participate study 1 . Patients history chemotherapy ( include estramustine phosphate sodium hydrate ( JAN ) ) treatment enzalutamide abiraterone acetate 2 . Patients history steroid usage treatment prostate cancer 3 . Patients history 5alphareductase inhibitor , estrogen steroidal antiandrogen within past 4 week prior initial administration enzalutamide 4 . Patients history malignant tumor prostate cancer within past 3 year 5 . Patients history seizure predispose disease seizure 6 . Patients severe liver dysfunction 7 . Patients previous history hypersensitivity component drug administer study 8 . Patients consider inappropriate study participation investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>